CEL-SCI reveals pricing details for $10 million public offering
Public Offering Announcement: CEL-SCI Corporation has announced a public offering of 1,111,200 shares of its common stock.
Pricing Details: Each share is priced at $9.00, leading to total gross proceeds of approximately $10 million before expenses.
Closing Date: The offering is expected to close on August 29, 2025.
Additional Information: The announcement includes references to previous offerings and financial data related to CEL-SCI.
Trade with 70% Backtested Accuracy
Analyst Views on CVM
About CVM
About the author
Cel-Sci CEO Buys Shares, Stock Rises 7%
- CEO Share Purchase: Cel-Sci's CEO Geert R. purchased 38,023 shares at $5.26 each on January 22 for approximately $200,000, increasing his total holdings to 120,815 shares, reflecting confidence in the company's future prospects.
- Clinical Trial Preparation: The company is preparing for a confirmatory registration study for its experimental cancer treatment Multikine, aiming to enroll 212 patients with newly diagnosed resectable head and neck cancer, with enrollment expected to begin in spring 2026 and potential approval by 2028 based on generated data.
- Improved Financial Performance: For the fiscal year ending in September, Cel-Sci reported a net loss of $25.4 million, down from $27.6 million in fiscal 2024, indicating efforts to control costs and improve financial health.
- Positive Market Sentiment: On Stocktwits, retail sentiment around CVM stock remained in the 'bullish' territory, with message volume rising from 'high' to 'extremely high', suggesting investor optimism about the company's future developments.
CEL-SCI Files for Breakthrough Designation for Multikine in Saudi Arabia, Plans 212-Patient Enrollment in 2026
- Clinical Trial Progress: CEL-SCI is preparing for a 212-patient Confirmatory Registration Study for newly diagnosed head and neck cancer patients, with enrollment expected to begin in Spring 2026, paving the way for potential early approval in the U.S. and significantly enhancing market competitiveness.
- Survival Rate Improvement: Multikine demonstrated a long-term survival rate of 73% in prior Phase 3 studies compared to 45% in the control group, significantly reducing the risks associated with developing cancer therapies and boosting investor confidence.
- Market Expansion in Saudi Arabia: CEL-SCI has applied for Breakthrough Medicine Designation in Saudi Arabia and is collaborating with a local company to support the Kingdom's Vision 2030, further solidifying its leadership position in the global biotechnology sector.
- Financial Condition Improvement: As of September 30, 2025, CEL-SCI's net loss decreased to $25.4 million, with R&D expenses down 13%, reflecting the company's proactive efforts in cost control and resource optimization.
Emerging Growth Stocks Experience Significant Gains in After-Hours Trading
Adaptimmune Therapeutics Surge: Adaptimmune Therapeutics plc (ADAP) saw a dramatic after-hours increase of 30% following a nearly 98% gain during regular trading, driven by renewed investor interest despite no specific news. The company reported a net loss of $30.3 million for Q2 2025 but has made strategic moves, including selling cell therapies for $55 million.
Butterfly Network Recognition: Butterfly Network Inc. (BFLY) rose 10.58% in after-hours trading after being named one of TIME's Top HealthTech Companies for 2025, alongside a recent appointment of a new CTO. The company’s technology has been validated by a JAMA study showing significant reductions in hospital stays and costs.
Aquestive Therapeutics Positive Outlook: Aquestive Therapeutics Inc. (AQST) continued its upward trend with a 7.69% increase in after-hours trading, bolstered by FDA confirmation that no advisory committee meeting is needed for its NDA for Anaphylm, streamlining the approval process. The company also secured $75 million in strategic funding.
Insider Confidence at ALX Oncology: ALX Oncology Holdings Inc. (ALXO) gained 9.17% in after-hours trading, attributed to insider buying by CEO Jason Lettmann, signaling confidence in the company. ALXO's lead candidate, Evorpacept, is currently in multiple clinical trials, maintaining investor interest despite no new data releases.
Stock Market Update: Nvidia Weighs on Nasdaq Futures—Attention on Dollar General, Dell, and Best Buy
Market Overview: U.S. stock futures showed mixed results following gains from the previous day, with Nvidia Corp. experiencing a decline despite reporting better-than-expected second-quarter results.
Nvidia's Performance: Nvidia's stock fell due to lack of guidance on H20 shipments to China and weaker data center revenue, although analysts remain optimistic about its leadership in AI infrastructure.
Economic Indicators: The 10-year Treasury bond yield was at 4.23%, with markets anticipating an 87.3% chance of interest rate cuts by the Federal Reserve in September; mortgage applications also saw a slight decline.
Stock Movements: Notable stock movements included MongoDB Inc. rising 38% after strong earnings, while Kohl’s Corp. gained 24%. Conversely, CEL-SCI Corp. dropped 30.83% after announcing a public offering.
Snowflake Shares Surge 14%; Check Out 20 Stocks Making Moves in Premarket Trading
Snowflake Inc. Financial Results: Snowflake's shares surged 14.2% in pre-market trading after reporting second-quarter revenue of $1.14 billion and adjusted earnings of 35 cents per share, both exceeding analyst expectations.
Other Gainers in Pre-Market Trading: Several stocks saw significant gains, including Erayak Power Solution Group (up 52.5%), Top KingWin Ltd (up 50.5%), and Telomir Pharmaceuticals (up 43.9%).
Notable Losers in Pre-Market Trading: CEL-SCI Corporation experienced a sharp decline of 29.8% following a public offering announcement, while The Cooper Companies and Cognition Therapeutics also reported losses of 14.5% and 14.1%, respectively.
NVIDIA's Performance: NVIDIA shares fell 2% despite reporting better-than-expected earnings and projecting third-quarter revenue within the consensus estimate range.
What’s Causing the After-Hours Plunge in CEL-SCI Stock?
Stock Price Decline: CEL-SCI Corporation's shares fell 38.19% to $8.06 after announcing a $10 million public offering priced below market levels.
Offering Details: The company priced 1,111,200 common shares at $9.00 each, a 30.9% discount from the previous closing price of $13.04, with the offering expected to close on August 29.
Use of Proceeds: Funds from the offering will be used for the development of Multikine, a cancer immunotherapy candidate, as well as general corporate purposes and working capital.
Market Performance: Over the past year, CEL-SCI's stock has fluctuated between $1.98 and $39.30, with a current market capitalization of $89.74 million.
Cel-Sci CEO Buys Shares, Stock Rises 7%
- CEO Share Purchase: Cel-Sci's CEO Geert R. purchased 38,023 shares at $5.26 each on January 22 for approximately $200,000, increasing his total holdings to 120,815 shares, reflecting confidence in the company's future prospects.
- Clinical Trial Preparation: The company is preparing for a confirmatory registration study for its experimental cancer treatment Multikine, aiming to enroll 212 patients with newly diagnosed resectable head and neck cancer, with enrollment expected to begin in spring 2026 and potential approval by 2028 based on generated data.
- Improved Financial Performance: For the fiscal year ending in September, Cel-Sci reported a net loss of $25.4 million, down from $27.6 million in fiscal 2024, indicating efforts to control costs and improve financial health.
- Positive Market Sentiment: On Stocktwits, retail sentiment around CVM stock remained in the 'bullish' territory, with message volume rising from 'high' to 'extremely high', suggesting investor optimism about the company's future developments.
CEL-SCI Files for Breakthrough Designation for Multikine in Saudi Arabia, Plans 212-Patient Enrollment in 2026
- Clinical Trial Progress: CEL-SCI is preparing for a 212-patient Confirmatory Registration Study for newly diagnosed head and neck cancer patients, with enrollment expected to begin in Spring 2026, paving the way for potential early approval in the U.S. and significantly enhancing market competitiveness.
- Survival Rate Improvement: Multikine demonstrated a long-term survival rate of 73% in prior Phase 3 studies compared to 45% in the control group, significantly reducing the risks associated with developing cancer therapies and boosting investor confidence.
- Market Expansion in Saudi Arabia: CEL-SCI has applied for Breakthrough Medicine Designation in Saudi Arabia and is collaborating with a local company to support the Kingdom's Vision 2030, further solidifying its leadership position in the global biotechnology sector.
- Financial Condition Improvement: As of September 30, 2025, CEL-SCI's net loss decreased to $25.4 million, with R&D expenses down 13%, reflecting the company's proactive efforts in cost control and resource optimization.
Emerging Growth Stocks Experience Significant Gains in After-Hours Trading
Adaptimmune Therapeutics Surge: Adaptimmune Therapeutics plc (ADAP) saw a dramatic after-hours increase of 30% following a nearly 98% gain during regular trading, driven by renewed investor interest despite no specific news. The company reported a net loss of $30.3 million for Q2 2025 but has made strategic moves, including selling cell therapies for $55 million.
Butterfly Network Recognition: Butterfly Network Inc. (BFLY) rose 10.58% in after-hours trading after being named one of TIME's Top HealthTech Companies for 2025, alongside a recent appointment of a new CTO. The company’s technology has been validated by a JAMA study showing significant reductions in hospital stays and costs.
Aquestive Therapeutics Positive Outlook: Aquestive Therapeutics Inc. (AQST) continued its upward trend with a 7.69% increase in after-hours trading, bolstered by FDA confirmation that no advisory committee meeting is needed for its NDA for Anaphylm, streamlining the approval process. The company also secured $75 million in strategic funding.
Insider Confidence at ALX Oncology: ALX Oncology Holdings Inc. (ALXO) gained 9.17% in after-hours trading, attributed to insider buying by CEO Jason Lettmann, signaling confidence in the company. ALXO's lead candidate, Evorpacept, is currently in multiple clinical trials, maintaining investor interest despite no new data releases.
Stock Market Update: Nvidia Weighs on Nasdaq Futures—Attention on Dollar General, Dell, and Best Buy
Market Overview: U.S. stock futures showed mixed results following gains from the previous day, with Nvidia Corp. experiencing a decline despite reporting better-than-expected second-quarter results.
Nvidia's Performance: Nvidia's stock fell due to lack of guidance on H20 shipments to China and weaker data center revenue, although analysts remain optimistic about its leadership in AI infrastructure.
Economic Indicators: The 10-year Treasury bond yield was at 4.23%, with markets anticipating an 87.3% chance of interest rate cuts by the Federal Reserve in September; mortgage applications also saw a slight decline.
Stock Movements: Notable stock movements included MongoDB Inc. rising 38% after strong earnings, while Kohl’s Corp. gained 24%. Conversely, CEL-SCI Corp. dropped 30.83% after announcing a public offering.
Snowflake Shares Surge 14%; Check Out 20 Stocks Making Moves in Premarket Trading
Snowflake Inc. Financial Results: Snowflake's shares surged 14.2% in pre-market trading after reporting second-quarter revenue of $1.14 billion and adjusted earnings of 35 cents per share, both exceeding analyst expectations.
Other Gainers in Pre-Market Trading: Several stocks saw significant gains, including Erayak Power Solution Group (up 52.5%), Top KingWin Ltd (up 50.5%), and Telomir Pharmaceuticals (up 43.9%).
Notable Losers in Pre-Market Trading: CEL-SCI Corporation experienced a sharp decline of 29.8% following a public offering announcement, while The Cooper Companies and Cognition Therapeutics also reported losses of 14.5% and 14.1%, respectively.
NVIDIA's Performance: NVIDIA shares fell 2% despite reporting better-than-expected earnings and projecting third-quarter revenue within the consensus estimate range.
What’s Causing the After-Hours Plunge in CEL-SCI Stock?
Stock Price Decline: CEL-SCI Corporation's shares fell 38.19% to $8.06 after announcing a $10 million public offering priced below market levels.
Offering Details: The company priced 1,111,200 common shares at $9.00 each, a 30.9% discount from the previous closing price of $13.04, with the offering expected to close on August 29.
Use of Proceeds: Funds from the offering will be used for the development of Multikine, a cancer immunotherapy candidate, as well as general corporate purposes and working capital.
Market Performance: Over the past year, CEL-SCI's stock has fluctuated between $1.98 and $39.30, with a current market capitalization of $89.74 million.
